Large Language Models (LLMs) are revolutionizing medical Question-Answering (medQA) through extensive use of medical literature. However, their performance is often hampered by outdated training data and a lack of explainability, which limits clinical applicability. This study aimed to create and assess UroBot, a urology-specialized chatbot, by comparing it with state-of-the-art models and the performance of urologists on urological board questions, ensuring full clinician-verifiability. UroBot was developed using OpenAI's GPT-3.5, GPT-4, and GPT-4o models, employing retrieval-augmented generation (RAG) and the latest 2023 guidelines from the European Association of Urology (EAU). The evaluation included ten runs of 200 European Board of Urology (EBU) In-Service Assessment (ISA) questions, with performance assessed by the mean Rate of Correct Answers (RoCA). UroBot-4o achieved an average RoCA of 88.4%, surpassing GPT-4o by 10.8%, with a score of 77.6%. It was also clinician-verifiable and exhibited the highest run agreement as indicated by Fleiss' Kappa (k = 0.979). By comparison, the average performance of urologists on board questions, as reported in the literature, is 68.7%. Uro
Thanks to the rapidly evolving integration of LLMs into decision-support tools, a significant transformation is happening across large-scale systems. Like other medical fields, the use of LLMs such as GPT-4 is gaining increasing interest in radiation oncology as well. An attempt to assess GPT-4's performance in radiation oncology was made via a dedicated 100-question examination on the highly specialized topic of radiation oncology physics, revealing GPT-4's superiority over other LLMs. GPT-4's performance on a broader field of clinical radiation oncology is further benchmarked by the ACR Radiation Oncology In-Training (TXIT) exam where GPT-4 achieved a high accuracy of 74.57%. Its performance on re-labelling structure names in accordance with the AAPM TG-263 report has also been benchmarked, achieving above 96% accuracies. Such studies shed light on the potential of LLMs in radiation oncology. As interest in the potential and constraints of LLMs in general healthcare applications continues to rise5, the capabilities and limitations of LLMs in radiation oncology decision support have not yet been fully explored.
The European Research and Development for Space based High Contrast Imaging II Workshop, held at MPIA in May 2025, advanced Europe strategic coordination in support of future exoplanet imaging missions such as the Habitable Worlds Observatory and the Large Interferometer for Exoplanets mission. Building on the first 2024 workshop, this meeting defined concrete priorities across eight technical areas, including wavefront sensing, coronagraphs, post processing, nulling interferometry, deformable mirrors, detectors, and telescope design. Discussions emphasized Europe strengths in adaptive optics, ground-based facilities, and interferometry, while identifying key gaps, particularly the need for a dedicated European vacuum testbed for high contrast imaging. The community highlighted near infrared or UV coronagraphy as a promising domain for European leadership and called for joint development of advanced data reduction algorithms, detectors, and cross-mission coordination with HWO and LIFE. The workshop outcomes establish a collaborative roadmap to strengthen Europe technological readiness, foster agency partnerships, and ensure its continued leadership in the next generation of space-b
Mathematical oncology is an interdisciplinary research field where the mathematical sciences meet cancer research. Being situated at the intersection of these two fields makes mathematical oncology highly dynamic, as practicing researchers are incentivised to quickly adapt to both technical and medical research advances. Determining the scope of mathematical oncology is therefore not straightforward; however, it is important for purposes related to funding allocation, education, scientific communication, and community organisation. To address this issue, we here conduct a bibliometric analysis of mathematical oncology. We compare our results to the broader field of mathematical biology, and position our findings within theoretical science of science frameworks. Based on article metadata and citation flows, our results provide evidence that mathematical oncology has undergone a significant evolution since the 1960s marked by increased interactions with other disciplines, geographical expansion, larger research teams, and greater diversity in studied topics. The latter finding contributes to the greater discussion on which models different research communities consider to be valuable
Energy system optimization models are indispensable for planning the European energy transition. Yet their applicability is constrained by the fundamental trade-off between spatial detail and computational tractability. Modelers often tackle this by spatially aggregating electricity networks. Existing methods, however, neglect differences in voltage levels, reducing them to a single level and thereby overlooking the critical role of transformers in expansion planning. Therefore, we propose a novel voltage-aware network partitioning and aggregation methodology that preserves individual voltage levels and transformers. We demonstrate the effectiveness of this approach and compare it against a voltage-unaware grid aggregation by solving a network expansion problem for a European case study using PyPSA. Our findings show that the proposed methodology preserves up to 70% of the transformer expansion costs in the aggregated model compared to the full grid model, thereby significantly improving the accuracy of investment decisions for transformers in the aggregated grid.
This document is submitted as input to the European Strategy for Particle Physics Update (ESPPU). The U.S.-based Electron-Ion Collider (EIC) aims at understanding how the complex dynamics of confined quarks and gluons makes up nucleons, nuclei and all visible matter, and determines their macroscopic properties. In April 2024, the EIC project received approval for critical-decision 3A (CD-3A) allowing for Long-Lead Procurement, bringing its realization another step closer. The ePIC Collaboration was established in July 2022 around the realization of a general purpose detector at the EIC. The EIC is based in U.S.A. but is characterized as a genuine international project. In fact, a large group of European scientists is already involved in the EIC community: currently, about a quarter of the EIC User Group (consisting of over 1500 scientists) and 29% of the ePIC Collaboration (consisting of $\sim$1000 members) is based in Europe. This European involvement is not only an important driver of the EIC, but can also be beneficial to a number of related ongoing and planned particle physics experiments at CERN. In this document, the connections between the scientific questions addressed at C
The Proton Improvement Plan (PIP-II) to the FNAL accelerator chain and the Long-Baseline Neutrino Facility (LBNF) will provide the world's most intense neutrino beam to the Deep Underground Neutrino Experiment (DUNE) enabling a wide-ranging physics program. This document outlines the significant contributions made by European national laboratories and institutes towards realizing the first phase of the project with a 1.2 MW neutrino beam. Construction of this first phase is well underway. For DUNE Phase II, this will be closely followed by an upgrade of the beam power to > 2 MW, for which the European groups again have a key role and which will require the continued support of the European community for machine aspects of neutrino physics. Beyond the neutrino beam aspects, LBNF is also responsible for providing unique infrastructure to install and operate the DUNE neutrino detectors at FNAL and at the Sanford Underground Research Facility (SURF). The cryostats for the first two Liquid Argon Time Projection Chamber detector modules at SURF, a contribution of CERN to LBNF, are central to the success of the ongoing execution of DUNE Phase I. Likewise, successful and timely procurem
Personalized oncology aims to tailor treatment strategies to the unique molecular and clinical profiles of individual patients, moving beyond the traditional paradigm of treating the disease not the patient. Achieving this vision requires the integration and interpretation of vast, heterogeneous biomedical data within a meaningful scientific framework. Knowledge graphs, structured according to biomedical ontologies, offer a powerful approach to contextualize and interconnect diverse datasets, enabling more precise and informed clinical decision-making. We present ECKO (Explainable Clinical Knowledge for Oncology), a comprehensive knowledge graph that integrates 33 biomedical ontologies and aggregates data from multiple studies to create a unified resource optimized for data-driven clinical applications in oncology. Designed to support personalized drug recommendations, ECKO facilitates the identification of optimal therapeutic options by linking patient-specific molecular data to relevant pharmacological knowledge. It provides transparent, interpretable explanations for drug recommendations, fostering greater trust and understanding among clinicians and researchers. This resource r
We present the Radiation Oncology NLP Database (ROND), the first dedicated Natural Language Processing (NLP) dataset for radiation oncology, an important medical specialty that has received limited attention from the NLP community in the past. With the advent of Artificial General Intelligence (AGI), there is an increasing need for specialized datasets and benchmarks to facilitate research and development. ROND is specifically designed to address this gap in the domain of radiation oncology, a field that offers many opportunities for NLP exploration. It encompasses various NLP tasks including Logic Reasoning, Text Classification, Named Entity Recognition (NER), Question Answering (QA), Text Summarization, and Patient-Clinician Conversations, each with a distinct focus on radiation oncology concepts and application cases. In addition, we have developed an instruction-tuning dataset consisting of over 20k instruction pairs (based on ROND) and trained a large language model, CancerChat. This serves to demonstrate the potential of instruction-tuning large language models within a highly-specialized medical domain. The evaluation results in this study could serve as baseline results for
This document represents a contribution of the United States early career collider physics community to the 2025--2026 update to the European Strategy for Particle Physics. Preferences with regard to different future collider options and R&D priorities were assessed via a survey. The early career community was defined as anyone who is a graduate student, postdoctoral researcher, untenured faculty member, or research scientist under 40 years of age. In total, 105 participants responded to the survey between February and March 10th, 2025. Questions were formulated primarily to gauge the enthusiasm and preferences for different collider options in line with the recommendations of the United States' P5 report, relevant to the European Strategy Update.
The search for dark matter is an exciting topic that is pursued in different communities over a wide range of masses and using a variety of experimental approaches. The result is a strongly correlated matrix of activities across Europe and beyond, both on the experimental and the theoretical side. We suggest to encourage and foster the collaboration of the involved institutions on technical, scientific and organisational level, in order to realise the synergies that are required to increase the impact of dark matter research and to cope with the increasing experiment sizes. The suggested network -- loosely titled "DMInfraNet" -- could be realised as a new initiative of the European strategy or be based on existing structures like iDMEu or DRD. The network can also serve as a nucleus for future joint funding proposals.
Heavy-flavour physics is an essential component of the particle-physics programme, offering critical tests of the Standard Model and far-reaching sensitivity to physics beyond it. Experiments such as LHCb, Belle II, and BESIII drive progress in the field, along with contributions from ATLAS and CMS. The LHCb Upgrade II and upgraded Belle II experiments will provide unique and highly sensitive measurements for decades, playing a key role in the searches for new physics. Future facilities with significant heavy-flavour capabilities will further expand these opportunities. We advocate for a European Strategy that fully supports Upgrade II of LHCb and an upgrade of Belle II, along with their subsequent exploitation. Additionally, we support a long-term plan that fully integrates flavour physics in an $e^+e^-$ collider to run as a $Z$ factory.
The Brazilian High-Energy Physics (HEP) community has expanded remarkably since its first involvement at CERN and Fermilab in the 1980s. Its recent organization under the Brazilian Network for High-Energy Physics (RENAFAE), since 2008, has further strengthened its scientific and technological goals, particularly in detector instrumentation, computing, and industry partnerships. In 2024, Brazil became an Associate Member State of CERN, opening new opportunities for deeper engagement in accelerator and detector R&D. This input to the 2026 update of the European Strategy for Particle Physics highlights Brazil's current participation in LHC experiments as well as ongoing developments in detector and accelerator technology, and details the community's view towards future colliders. The potential for expanded scientific and industrial collaborations between Brazil and CERN is also discussed.
The LISA mission is an international collaboration between ESA, its member states, and NASA, for the detection of gravitational waves from space. It was adopted in January 2024 and is scheduled for launch in the mid-2030's. It will be a constellation of three identical spacecraft forming a near-equilateral triangle in an heliocentric orbit, transferring laser beams over $2.5 \cdot 10^6$ km long arms. Laser interferometry is used to track separations between test masses, thus measuring spacetime strain variations as a function of time. LISA Science Objectives tackle many open questions in astrophysics, fundamental physics and cosmology, including ESA's Cosmic Vision questions "What are the fundamental laws of the universe?" and "How did the universe originate and of what is it made?". In this contribution, based on the LISA Red Book, we present a summary of the LISA Science Objectives relevant for the European Strategy for Particle Physics.
In view of the European Strategy for Particle Physics process, the French HEP community has organized a national process of collecting written contributions and has pursued a series of workshops culminating with a national symposium held in Paris on January 20-21, 2025 that involved over 280 scientists https://indico.in2p3.fr/event/34662/. The present document summarises the main conclusions of this bottom-up approach centred on the physics and technology motivations.
The European Strategy for Particle Physics (ESPP) - 2026 update is taking place in a turbulent international climate. Many of the norms that have governed relations between states for decades are being broken or challenged. The future progress of science in general, and particle physics in particular, will depend on our ability to maintain peaceful international scientific collaboration in the face of political pressures. We plead that the ESPP 2026 update acknowledge explicitly the importance of peaceful international scientific collaboration, not only for the progress of science, but also as a precious bridge between geopolitical blocs. "Scientific thought is the common heritage of mankind" - Abdus Salam
The essence of precision oncology lies in its commitment to tailor targeted treatments and care measures to each patient based on the individual characteristics of the tumor. The inherent heterogeneity of tumors necessitates gathering information from diverse data sources to provide valuable insights from various perspectives, fostering a holistic comprehension of the tumor. Over the past decade, multimodal data integration technology for precision oncology has made significant strides, showcasing remarkable progress in understanding the intricate details within heterogeneous data modalities. These strides have exhibited tremendous potential for improving clinical decision-making and model interpretation, contributing to the advancement of cancer care and treatment. Given the rapid progress that has been achieved, we provide a comprehensive overview of about 300 papers detailing cutting-edge multimodal data integration techniques in precision oncology. In addition, we conclude the primary clinical applications that have reaped significant benefits, including early assessment, diagnosis, prognosis, and biomarker discovery. Finally, derived from the findings of this survey, we presen
Axions and other very weakly interacting slim (with $m <$ 1 GeV) particles (WISPs) are a common feature of several extensions of the Standard Model of Particle Physics. The search of WISPs was already recommended in the last update of the European strategy on particle physics (ESPP). After that, the physics case for WISPs has gained additional momentum. Indeed, WISPs may provide a new paradigm to explain the nature of dark matter and puzzling astrophysical and particle physics observations. This document briefly summarizes current searches for WISPs and the perspectives in this research field for the next decade, ranging from their theoretical underpinning, over their indirect observational consequences in astrophysics, to their search in laboratory experiments. It is stressed that in Europe a rich, diverse, and low-cost experimental program is already underway with the potential for one or more game-changing discoveries. In this context, it is also reported the role of the EU funded COST Action ''Cosmic WISPers in the Dark Universe: Theory, astrophysics, and experiments'' (CA21106, https://www.cost.eu/actions/CA21106) in coordinating and supporting WISPs searches in Europe, sha
In Regional Economics, the attractiveness of regions for capital, migrants, tourists, and other kinds of flows is a relevant topic. Usually, studies in this field explore single flows, characterizing the dimensions of territorial attractiveness separately, rarely considering the interwoven effect of flows. Here, we investigate attractiveness from a multi-dimensional perspective (i.e., dealing with different flows), asking how various types of regional flows collectively shape the attractiveness dynamics of European regions. We analyze eight distinct flow types across NUTS2 regions from 2010 to 2018, employing a multilayer network approach. Notably, the multilayer approach unveils insights that would be missed in single-layer analyses. Community detection reveals complex structures that demonstrate the cohesive power of national borders and the existence of strong cross-border ties in specific regions. Our study contributes to a more nuanced understanding of regional attractiveness, with implications for targeted policy interventions in regional development and European cohesion.
In the era of targeted therapy, there has been increasing concern about the development of oncology drugs based on the "more is better" paradigm, developed decades ago for chemotherapy. Recently, the US Food and Drug Administration (FDA) initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development. To accommodate this paradigm shifting, we propose a dose-ranging approach to optimizing dose (DROID) for oncology trials with targeted drugs. DROID leverages the well-established dose-ranging study framework, which has been routinely used to develop non-oncology drugs for decades, and bridges it with established oncology dose-finding designs to optimize the dose of oncology drugs. DROID consists of two seamlessly connected stages. In the first stage, patients are sequentially enrolled and adaptively assigned to investigational doses to establish the therapeutic dose range (TDR), defined as the range of doses with acceptable toxicity and efficacy profiles, and the recommended phase 2 dose set (RP2S). In the second stage, patients are randomized to the doses in RP2S to assess the dose-response relationship and identify the optimal dose.